|
市場調査レポート
心血管疾患における幹細胞研究：2009年
Stem Cells for Cardiovascular Disease 2009 Market Report
|
Abstract
This is the latest and most up-to-date Worldwide Stem Cells Market Report from
Select Biosciences, based on our continual industry coverage. Select
Biosciences industry coverage in this report focuses on the technical, market,
and clinical trials aspects of stem cells being developed for addressing the
opportunities in the cardio and vascular disease spaces. Major emphasis is
placed on the various clinical applications of mesenchymal stem cells
(MSCs)ä€"a key stem cell lineage of paramount importance for
regenerative medicine. A Major Focus of this Report is on the Market Landscape
and Quantitative Market Trends in Cardiovascular Disease utilizing various
types of stem cell classes/lineages. Another key focus of this report is on
the various clinical trials either completed or in progress addressing
different therapeutic areas across the cardiovascular diseases landscape.
Extensive Worldwide Market Analyses Presented in this Report:
- Results and Analyses from Stem Cells-Focused Market Surveys Administered
to Large Respondent Pools of Industry Participants focused on Stem
Cellsä€ "Qualitative and Quantitative Market Trends are Analyzed and
Presented focusing on the cardiovascular disease spaces
- Breakout of the Market by Types of Stem Cells Utilized and Application
Areasä€ "in various therapeutic segments of the cardiovascular
disease therapeutics marketplace
- Quantitative Breakout of various types of stem cells in research and
clinical development for cardiovascular diseases
- Breakout of the Market by Therapeutic/Disease Segments
Addressedä€ "in the various segments of the cardiovascular disease
space
- Worldwide Stem Cells-focused Clinical Trials for Cardiovascular Diseases
- Qualitative and Quantitative Trends
- Sponsoring Institutions/Companies
- Types of Trials
- Types of Cells Utilized
- Clinical End-Points
- Progress Reports
- Competitive Landscape: Companies Focused on Developing Stem Cells-focused
Cellular Therapies for Different Disease Areas in the Cardiovascular
Spaceä€ "Qualitative and Quantitative Analyses
- Impact of Mesenchymal Stem Cells (MSCs) and other stem/progenitor cell
types for mediating cardiovascular disease regenerative medicine
- Mechanisms of action of MSCs in cardiovascular disease regenerative
medicine
- Delivery approaches for cellular therapy of cardiovascular diseases
Companies Profiled in This Market Report:
- Aastrom Biosciences
- Aldagen
- Angioblast Systems
- Arteriocyte
- Athersys
- Bioheart
- Cytori
- Geron
- Medistem
- Mytogen
- Osiris Therapeutics
- Pluristem
- t2cure
- TheraVitae
Table of Contents
Chapter 1. Executive Overview of the Space
- Scope of this Market Report
- Challenges in the Cellular Therapy Space
- Cardiovascular Disease Market Segmentation
- Cardiovascular Disease Market Opportunity
- Embryonic Stem Cell (ESC) Differentiation into Multiple Cellular
Chapter 2. Mesenchymal Stem Cells (MSCs) for Regenerative Medicine
- MSCs: Definition and Properties
- MSC Phenotype
- Heart Cell Lineage Diversification
- Pericytes: Tissue-Specific Progenitors
- Mechanisms of MSC-mediated Tissue Repair
- Fetal versus Adult MSCs
Chapter 3. Stem Cells for Cardiovascular Disease: Technology Landscape, Market Landscape, Clinical Trials Landscape
- Cellular Therapy for Cardiovascular Diseases
- Proposed Mechanisms of MSC-mediated Cardiovascular Repair
- Potential Delivery Routes of MSC-based Cellular Therapy for Cardiovascular
Diseases
- Safety Concerns with Stem Cell Therapy for Cardiovascular Disease
- Quantitative Market Analysis of the Cardiovascular Regenerative Medicine
Space
- Stem Cells for Cardiovascular Disease: Clinical Trials Landscape
Chapter 4. Stem Cells for Cardiovascular Disease: Selected Industry Events and Companies in the Space
- Selected Industry Events in Cardiovascular Cellular Therapy Sapce
- Profiles of Companies in the Cardiovascular Cellular Therapy Space
Appendix 1. Research Methodology
Appendix 2. Stem Cells for Cardiovascular Disease: Worldwide Clinical Trials Details
Appendix 3. Cardiovascular Disease Patient Population Statisstics
|
